Gastrooesophageal cancer+1
Not recruitingStudy of Pembrolizumab, Trastuzumab, and Drug Combination for Patients with HER2-Positive, Localized Esophagogastric Cancer
Study of Pembrolizumab, Trastuzumab, and Drug Combination for Patients with HER2-Positive, Localized Esophagogastric Cancer
- Disease:Gastrooesophageal cancerHER2 positive gastric cancer
- Substances:DocetaxelFluorouracil+3
Germany- Participants:18–64 years · 65+ years
- Substances:Docetaxel
- Sponsor:Frankfurter Institut Fuer Klinische Krebsforschung IKF GmbH









